We have updated our Terms of Use.
Please read our new Privacy Statement before continuing.

Cure for what ails

23 January 2009 By Rob Cox

A Pfizer deal with Wyeth would illustrate the merits of merging when economies are slowing or shrinking. A deal done mostly in stock, slicing out padding in costs and R&D, would benefit both sets of shareholders. This looks like a taste of deals to come.

This content is for Subscribers only


Email a friend

Please complete the form below.

Required fields *


(Separate multiple email addresses with commas)